

AMENDMENT

In the Claims

✓ ✓ ✓
Cancel claims 33-35, 56 and 59 without prejudice to or disclaimer of the subject matter therein.

Add new claims 61-64.

Sub G1) F1 61. (New) The composition of claim 32, wherein the fatty acid-acylated insulin is N-palmitoyl Lys^{B29} human insulin, and wherein the solution comprises from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

62. (New) The composition of claim 61, wherein the concentration of phenolic compound is from about 2.5 mg to about 5.0 mg per milliliter of the aqueous solution.

63. (New) The composition of claim 62, wherein the phenolic compound is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, methylparaben, and mixtures thereof.

Sub G8 64. (New) The composition of claim 63, wherein the phenolic preservative is selected from the group consisting of phenol and m-cresol.--

BEST AVAILABLE COPY

PENDING CLAIMS

27. (Once Amended) A composition comprising

- (a) a fatty acid-acylated insulin or a fatty acid-acylated insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted, and
- (b) zinc.

28. (Once Amended) A composition comprising an aqueous solution of

- (a) a fatty acid-acylated insulin or a fatty acid-acylated insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted, and
- (b) zinc.

29. (Once Amended) The composition of Claim 28, wherein the solution comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin or fatty acid-acylated insulin analog.

30. The composition of Claim 29, wherein the pH is 6.8 to 7.8.

31. (Once Amended) The composition of Claim 30, further comprising a phenolic compound at a concentration of from 0.5 mg to 5 mg per milliliter of the aqueous solution.

32. (Once Amended) The composition of Claim 31, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin, and wherein the fatty acid-acylated insulin analog is an N-acylated Lys^{B29} insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted.

57. The composition of claim 28, wherein the composition is a pharmaceutical composition that further comprises a phenolic compound, glycerol, and a pharmaceutically acceptable buffer.

58. (Once Amended) The composition of claim 27, wherein the composition comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin or fatty acid-acylated insulin analog.

60. (Once Amended) The composition of Claim 27, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin, and wherein the fatty acid-acylated insulin analog is an N-acylated Lys^{B29} insulin analog in which the amino acid residue at position B30 is Thr, Ala or deleted.

61. (Once Amended) The composition of claim 32, wherein the fatty acid-acylated insulin is N-myristoyl Lys^{B29} human insulin, and wherein the solution comprises from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

62. The composition of claim 61, wherein the concentration of phenolic compound is from about 2.5 mg to about 5.0 mg per milliliter of the aqueous solution.

63. The composition of claim 62, wherein the phenolic compound is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, methylparaben, and mixtures thereof.

64. (Once Amended) The composition of claim 63, wherein the phenolic compound is selected from the group consisting of phenol and m-cresol.

65. (New) The composition of Claim 27, wherein the fatty acid in the fatty acid-acylated analog is myristic acid.

66. (New) The composition of Claim 28, wherein the fatty acid in the fatty acid-acylated analog is myristic acid.

67. (New) The composition of claim 58, wherein the pH is 6.8 to 7.8.